Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMSW) Equity Average (2023 - 2025)

Historic Equity Average for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $753.3 million.

  • NewAmsterdam Pharma's Equity Average rose 9660.25% to $753.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.3 million, marking a year-over-year increase of 9660.25%. This contributed to the annual value of $522.9 million for FY2024, which is 4557.45% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its Equity Average stood at $753.3 million for Q3 2025, which was up 9660.25% from $777.9 million recorded in Q2 2025.
  • NewAmsterdam Pharma's 5-year Equity Average high stood at $777.9 million for Q2 2025, and its period low was $310.1 million during Q4 2023.
  • For the 3-year period, NewAmsterdam Pharma's Equity Average averaged around $499.5 million, with its median value being $399.6 million (2024).
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 2156.78% in 2024, then soared by 11920.48% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Equity Average (Quarter) stood at $310.1 million in 2023, then soared by 83.22% to $568.2 million in 2024, then skyrocketed by 32.58% to $753.3 million in 2025.
  • Its Equity Average stands at $753.3 million for Q3 2025, versus $777.9 million for Q2 2025 and $767.4 million for Q1 2025.